FY26 Appendix 4E and Annual Report
Filed with ASX · · 61 pages · English
Summary by 6ix AI
The report highlights a loss from ordinary activities after tax, alongside no dividends proposed for the year. Cambium Bio has maintained financial discipline, raising funds through placements and managing operating cash outflows effectively.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Cambium Bio
- Cambium Bio Raises A$1.0 Million via Placement
- FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
- Half Year Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Cambium Bio Secures A$2.4 Million Strategic Investment
Later from Cambium Bio
- Cambium Bio Secures A$10.85 Million Funding Package
- Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio